MAPK-IN-5

• Description :

  MAPK-IN-5 is a potent MAPK inhibitor with an IC50 of 1.35 μM against HeLa cells. MAPK-IN-5 inhibits HeLa cell proliferation by inducing ROS-mediated DNA damage and mitochondrial apoptosis via the MAPK pathway. MAPK-IN-5 significantly inhibits colony formation, reduces the number of live cells, suppresses cell migration, and causes cell cycle arrest in the G2/M phase in HeLa cells. MAPK-IN-5 can be used for the study of cervical cancer[1].

• UNSPSC :

  12352005

• Target :

  Apoptosis; Bcl-2 Family; Caspase; p38 MAPK; PARP; Reactive Oxygen Species (ROS)

• Related Pathways :

  Apoptosis; Cell Cycle/DNA Damage; Epigenetics; Immunology/Inflammation; MAPK/ERK Pathway; Metabolic Enzyme/Protease; NF-κB

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Smiles :

  COCCOC(C=C1N=CN=C2NC3=CC(C(N=N4)=CN4CC5=CC=C(C(F)(F)F)C=C5)=CC=C3)=C(C=C12)OCCOC

• Molecular Formula :

  C30H29F3N6O4

• Molecular Weight :

  594.58

• References & Citations :

  [1]Wang L, et al. Design, synthesis and anti-cancer activity of novel 1,2,3-triazole hybrids of erlotinib against cervical cancer via MAPK signaling pathway. Sci Rep. 2025 Jul 9;15 (1) :24582.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  Bcl-2; Caspase 3; Caspase 9; p38 MAPK; PARP1

• CAS Number :

  [2579683-39-7]